The sudden departure of FDA’s Peter Marks raises uncertainty across the biopharma sector amid ongoing regulatory scrutiny and …
The sudden departure of FDA’s Peter Marks raises uncertainty across the biopharma sector amid ongoing regulatory scrutiny and …
MaaT Pharma strengthens financial position to advance its microbiome-based therapies, focusing on acute graft-versus-host disease and hemato-oncology indications.
Long-term clinical data from Roche strengthen the case for disease-modifying therapies in spinal muscular atrophy and Duchenne muscular …
Promising clinical results highlight Gilead’s innovative approach to long-acting HIV treatment, aiming to improve patient adherence and outcomes.
Long-term data demonstrate that EBGLYSS offers durable skin improvement and symptom relief, reinforcing its role as a first-line …
Two key players in immunology and vaccine innovation gain financial momentum as they push forward with mRNA vaccines …
Roche introduces an ultra-rapid and scalable next-generation sequencing method poised to accelerate genomic research and potentially reshape clinical …
The FDA has cleared vimseltinib (Romvimza), a first-in-class CSF1R inhibitor, for symptomatic tenosynovial giant cell tumor—marking a breakthrough …
Grace Therapeutics reports that its Phase III STRIVE-ON trial showed GTx-104 significantly reduces clinically significant hypotension and improves …
On February 1, 2025, the U.S. Food and Drug Administration (FDA) approved Eli Lilly’s lebrikizumab, marking the first …
Already a subscriber? Log in